Investment
Features
FeesSafety
Academy
More
Pluang+

Kuya Silver grants 525,000 stock options to directors and advisor at C$0.50 each

Company Fundamentals
19 Oct 2026
Newsfile Corp
View Source
Neutral
Kuya Silver grants 525,000 stock options to directors and advisor at C$0.50 each

Kuya Silver Corporation has approved the issuance of 525,000 stock options at an exercise price of C$0.50 per share. Of these, 475,000 options are granted to independent directors as part of their annual equity incentive, expiring in five years, while 50,000 options are granted to a strategic advisor, expiring in two years. The options vest in three equal parts over two years and shares issued will have a hold period of four months plus one day. This move aligns with Kuya Silver's incentive plan to reward key contributors and support company growth in its silver mining operations in Peru and Canada.

Kuya Silver's stock option grant is the subject, with Pluang's Basic Materials sector data providing market context. As of Oct 20, 2026 03:42 WIB, among 83 priced Basic Materials-sector US stocks on Pluang, 31 rose and 51 fell. Notable movers include ALM at USD 8.81 with a -10.38% change, STLD at USD 229.00 with a -4.80% change, and CLMT at USD 55.23 with a -4.36% change and 100% buy order activity. The most notable figure is ALM's 10.38% decline.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
30 minutes ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
30 minutes ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
1 hour ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
2 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App